A real-world study on the clinicopathological profile, treatment outcomes and health-related quality of life, anxiety and depression among patients with desmoid tumor at two tertiary care centers in India
BackgroundThe medical management of DT comprises tyrosine kinase inhibitors (TKIs), hormonal agents, anti-inflammatory drugs with the recently approved gamma secretase inhibitor nirogacestat being the current standard of care. Real-world data on evolving treatment landscapes of DT remains scarce.Met...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-10-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1382856/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850275363112878080 |
|---|---|
| author | Ghazal Tansir Aparna Sharma Bivas Biswas Suryadev Narayan Sah Somnath Roy S. V. S. Deo Sandeep Agarwala Shah Alam Khan Sameer Bakhshi Deepam Pushpam |
| author_facet | Ghazal Tansir Aparna Sharma Bivas Biswas Suryadev Narayan Sah Somnath Roy S. V. S. Deo Sandeep Agarwala Shah Alam Khan Sameer Bakhshi Deepam Pushpam |
| author_sort | Ghazal Tansir |
| collection | DOAJ |
| description | BackgroundThe medical management of DT comprises tyrosine kinase inhibitors (TKIs), hormonal agents, anti-inflammatory drugs with the recently approved gamma secretase inhibitor nirogacestat being the current standard of care. Real-world data on evolving treatment landscapes of DT remains scarce.MethodsThis is a retrospective study of patients with DT registered between 1995 and 2020 at All India Institute of Medical Sciences, New Delhi and Tata Medical Center, Kolkata. Baseline characteristics were analyzed in form of median values and interquartile range. Categorical and continuous variables were compared by chi square and independent samples T- tests respectively. Anxiety, depression and QoL were prospectively measured among 30 patients using Hospital Anxiety and Depression (HADS) and Functional Assessment of Cancer Therapy-General (FACT-G) scales respectively between 2022 to 2023.Results200 patients were included with a male-predominant (n=111, 55.5%) population and median age 26.5 (2.5-75) years. Extremity (n=100, 50%) and abdomen (n=65, 32.5%) were commonest primary sites and median of 2 (1–4) lines of treatment were received. First-line included surgery (n=116, 58%), systemic therapy (n=67, 33.5%), radiotherapy (10, n=5%) and active surveillance (n=7, 3.5%). First-line systemic agents included tamoxifen (n=55, 27.5%), imatinib (n=7, 3.5%), sorafenib (n=1, 0.5%) and chemotherapy (n=4, 2%). 2019 onward, 3% and 63% underwent active surveillance and surgery respectively. Best radiological response obtained with tamoxifen was stable disease (SD) (n=76, 59%) and partial response (PR) (n=31, 24.2%). Best radiological response obtained with sorafenib was PR (n=17, 60.7%) and SD (n=9, 32.1%). Thirty patients underwent HADS and FACT-G scale assessment. Mean HADS-Anxiety subscale score was 3.6 (+/-3.9 SD) and HADS-Depression sub-scale score was 2.6 (+/-3.5 SD) with clinically significant anxiety and depression in 2 (6.7%) patients each. The overall mean FACT-G score was 87.5 (+/-12.6 SD) and lower mean physical well-being (p=0.006) and emotional well-being (0.017) scores were significantly associated with higher HADS-anxiety (>/=8) scores.ConclusionsAssessment of anxiety, depression and QoL are paramount to gauge the psychological impact of DT. This study gives an overview of clinical and management profile of patients with DT in India, with limitations of selection bias, heterogeneous population and small sample size for QoL assessment. |
| format | Article |
| id | doaj-art-e35a9dd3bdca44778e32f4181355d3be |
| institution | OA Journals |
| issn | 2234-943X |
| language | English |
| publishDate | 2024-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-e35a9dd3bdca44778e32f4181355d3be2025-08-20T01:50:45ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2024-10-011410.3389/fonc.2024.13828561382856A real-world study on the clinicopathological profile, treatment outcomes and health-related quality of life, anxiety and depression among patients with desmoid tumor at two tertiary care centers in IndiaGhazal Tansir0Aparna Sharma1Bivas Biswas2Suryadev Narayan Sah3Somnath Roy4S. V. S. Deo5Sandeep Agarwala6Shah Alam Khan7Sameer Bakhshi8Deepam Pushpam9Department of Medical Oncology, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, IndiaDepartment of Medical Oncology, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, IndiaDepartment of Medical Oncology, Tata Medical Center, Kolkata, West Bengal, IndiaDepartment of Medical Oncology, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, IndiaDepartment of Medical Oncology, Tata Medical Center, Kolkata, West Bengal, IndiaDepartment of Surgical Oncology, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, IndiaDepartment of Pediatric Surgery, All India Institute of Medical Sciences, New Delhi, IndiaDepartment of Orthopedics, All India Institute of Medical Sciences, New Delhi, IndiaDepartment of Medical Oncology, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, IndiaDepartment of Medical Oncology, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, IndiaBackgroundThe medical management of DT comprises tyrosine kinase inhibitors (TKIs), hormonal agents, anti-inflammatory drugs with the recently approved gamma secretase inhibitor nirogacestat being the current standard of care. Real-world data on evolving treatment landscapes of DT remains scarce.MethodsThis is a retrospective study of patients with DT registered between 1995 and 2020 at All India Institute of Medical Sciences, New Delhi and Tata Medical Center, Kolkata. Baseline characteristics were analyzed in form of median values and interquartile range. Categorical and continuous variables were compared by chi square and independent samples T- tests respectively. Anxiety, depression and QoL were prospectively measured among 30 patients using Hospital Anxiety and Depression (HADS) and Functional Assessment of Cancer Therapy-General (FACT-G) scales respectively between 2022 to 2023.Results200 patients were included with a male-predominant (n=111, 55.5%) population and median age 26.5 (2.5-75) years. Extremity (n=100, 50%) and abdomen (n=65, 32.5%) were commonest primary sites and median of 2 (1–4) lines of treatment were received. First-line included surgery (n=116, 58%), systemic therapy (n=67, 33.5%), radiotherapy (10, n=5%) and active surveillance (n=7, 3.5%). First-line systemic agents included tamoxifen (n=55, 27.5%), imatinib (n=7, 3.5%), sorafenib (n=1, 0.5%) and chemotherapy (n=4, 2%). 2019 onward, 3% and 63% underwent active surveillance and surgery respectively. Best radiological response obtained with tamoxifen was stable disease (SD) (n=76, 59%) and partial response (PR) (n=31, 24.2%). Best radiological response obtained with sorafenib was PR (n=17, 60.7%) and SD (n=9, 32.1%). Thirty patients underwent HADS and FACT-G scale assessment. Mean HADS-Anxiety subscale score was 3.6 (+/-3.9 SD) and HADS-Depression sub-scale score was 2.6 (+/-3.5 SD) with clinically significant anxiety and depression in 2 (6.7%) patients each. The overall mean FACT-G score was 87.5 (+/-12.6 SD) and lower mean physical well-being (p=0.006) and emotional well-being (0.017) scores were significantly associated with higher HADS-anxiety (>/=8) scores.ConclusionsAssessment of anxiety, depression and QoL are paramount to gauge the psychological impact of DT. This study gives an overview of clinical and management profile of patients with DT in India, with limitations of selection bias, heterogeneous population and small sample size for QoL assessment.https://www.frontiersin.org/articles/10.3389/fonc.2024.1382856/fullDesmoid tumortyrosine kinase inhibitorsoral metronomic therapyquality of liferare diseases |
| spellingShingle | Ghazal Tansir Aparna Sharma Bivas Biswas Suryadev Narayan Sah Somnath Roy S. V. S. Deo Sandeep Agarwala Shah Alam Khan Sameer Bakhshi Deepam Pushpam A real-world study on the clinicopathological profile, treatment outcomes and health-related quality of life, anxiety and depression among patients with desmoid tumor at two tertiary care centers in India Frontiers in Oncology Desmoid tumor tyrosine kinase inhibitors oral metronomic therapy quality of life rare diseases |
| title | A real-world study on the clinicopathological profile, treatment outcomes and health-related quality of life, anxiety and depression among patients with desmoid tumor at two tertiary care centers in India |
| title_full | A real-world study on the clinicopathological profile, treatment outcomes and health-related quality of life, anxiety and depression among patients with desmoid tumor at two tertiary care centers in India |
| title_fullStr | A real-world study on the clinicopathological profile, treatment outcomes and health-related quality of life, anxiety and depression among patients with desmoid tumor at two tertiary care centers in India |
| title_full_unstemmed | A real-world study on the clinicopathological profile, treatment outcomes and health-related quality of life, anxiety and depression among patients with desmoid tumor at two tertiary care centers in India |
| title_short | A real-world study on the clinicopathological profile, treatment outcomes and health-related quality of life, anxiety and depression among patients with desmoid tumor at two tertiary care centers in India |
| title_sort | real world study on the clinicopathological profile treatment outcomes and health related quality of life anxiety and depression among patients with desmoid tumor at two tertiary care centers in india |
| topic | Desmoid tumor tyrosine kinase inhibitors oral metronomic therapy quality of life rare diseases |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2024.1382856/full |
| work_keys_str_mv | AT ghazaltansir arealworldstudyontheclinicopathologicalprofiletreatmentoutcomesandhealthrelatedqualityoflifeanxietyanddepressionamongpatientswithdesmoidtumorattwotertiarycarecentersinindia AT aparnasharma arealworldstudyontheclinicopathologicalprofiletreatmentoutcomesandhealthrelatedqualityoflifeanxietyanddepressionamongpatientswithdesmoidtumorattwotertiarycarecentersinindia AT bivasbiswas arealworldstudyontheclinicopathologicalprofiletreatmentoutcomesandhealthrelatedqualityoflifeanxietyanddepressionamongpatientswithdesmoidtumorattwotertiarycarecentersinindia AT suryadevnarayansah arealworldstudyontheclinicopathologicalprofiletreatmentoutcomesandhealthrelatedqualityoflifeanxietyanddepressionamongpatientswithdesmoidtumorattwotertiarycarecentersinindia AT somnathroy arealworldstudyontheclinicopathologicalprofiletreatmentoutcomesandhealthrelatedqualityoflifeanxietyanddepressionamongpatientswithdesmoidtumorattwotertiarycarecentersinindia AT svsdeo arealworldstudyontheclinicopathologicalprofiletreatmentoutcomesandhealthrelatedqualityoflifeanxietyanddepressionamongpatientswithdesmoidtumorattwotertiarycarecentersinindia AT sandeepagarwala arealworldstudyontheclinicopathologicalprofiletreatmentoutcomesandhealthrelatedqualityoflifeanxietyanddepressionamongpatientswithdesmoidtumorattwotertiarycarecentersinindia AT shahalamkhan arealworldstudyontheclinicopathologicalprofiletreatmentoutcomesandhealthrelatedqualityoflifeanxietyanddepressionamongpatientswithdesmoidtumorattwotertiarycarecentersinindia AT sameerbakhshi arealworldstudyontheclinicopathologicalprofiletreatmentoutcomesandhealthrelatedqualityoflifeanxietyanddepressionamongpatientswithdesmoidtumorattwotertiarycarecentersinindia AT deepampushpam arealworldstudyontheclinicopathologicalprofiletreatmentoutcomesandhealthrelatedqualityoflifeanxietyanddepressionamongpatientswithdesmoidtumorattwotertiarycarecentersinindia AT ghazaltansir realworldstudyontheclinicopathologicalprofiletreatmentoutcomesandhealthrelatedqualityoflifeanxietyanddepressionamongpatientswithdesmoidtumorattwotertiarycarecentersinindia AT aparnasharma realworldstudyontheclinicopathologicalprofiletreatmentoutcomesandhealthrelatedqualityoflifeanxietyanddepressionamongpatientswithdesmoidtumorattwotertiarycarecentersinindia AT bivasbiswas realworldstudyontheclinicopathologicalprofiletreatmentoutcomesandhealthrelatedqualityoflifeanxietyanddepressionamongpatientswithdesmoidtumorattwotertiarycarecentersinindia AT suryadevnarayansah realworldstudyontheclinicopathologicalprofiletreatmentoutcomesandhealthrelatedqualityoflifeanxietyanddepressionamongpatientswithdesmoidtumorattwotertiarycarecentersinindia AT somnathroy realworldstudyontheclinicopathologicalprofiletreatmentoutcomesandhealthrelatedqualityoflifeanxietyanddepressionamongpatientswithdesmoidtumorattwotertiarycarecentersinindia AT svsdeo realworldstudyontheclinicopathologicalprofiletreatmentoutcomesandhealthrelatedqualityoflifeanxietyanddepressionamongpatientswithdesmoidtumorattwotertiarycarecentersinindia AT sandeepagarwala realworldstudyontheclinicopathologicalprofiletreatmentoutcomesandhealthrelatedqualityoflifeanxietyanddepressionamongpatientswithdesmoidtumorattwotertiarycarecentersinindia AT shahalamkhan realworldstudyontheclinicopathologicalprofiletreatmentoutcomesandhealthrelatedqualityoflifeanxietyanddepressionamongpatientswithdesmoidtumorattwotertiarycarecentersinindia AT sameerbakhshi realworldstudyontheclinicopathologicalprofiletreatmentoutcomesandhealthrelatedqualityoflifeanxietyanddepressionamongpatientswithdesmoidtumorattwotertiarycarecentersinindia AT deepampushpam realworldstudyontheclinicopathologicalprofiletreatmentoutcomesandhealthrelatedqualityoflifeanxietyanddepressionamongpatientswithdesmoidtumorattwotertiarycarecentersinindia |